Showing 1 - 6 of 6 Immune System Diseases
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System

Status: Open Not Enrolling

Investigator: Terry Clyburn

Study Coordinator: Adrienne New

Phone: 713.441.3250

This study is designed to observe the long term clinical outcomes of patient-specific knee arthroplasty in patients with osteoarthritis. ... Read more >

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Michelle Guthrie

Phone: 713.441.6564

Open label, multi-center dose escalation and dose expansion study designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor effects of ALRN-6924 in patients with advanced solid tumors or lymphomas with wild-typ ... Read more >

LIBERATE STUDY

Status: Open Not Enrolling

Investigator: Lisa Kopas

Study Coordinator: Adrienne New

Phone: 713.441.3250

The purpose of this research is to study a medical device that is designed to produce lung volume reduction. This device is called the PulmonX Endobronchial Valve (EBV). It has not been approved by the Food and Drug Administration (FDA) and is c ... Read more >

Post-market, Randomized, Open-Label, Multicenter, Study to Evaluate the Effectiveness of Closed Incision Negative Pressure Therapy Versus Standard of Care Dressings in Reducing Surgical Site Complications in Subjects With Revision of a Failed TKA

Status: Enrolling

Investigator: Stephen Incavo

Study Coordinator: Adrienne New

Phone: 713.441.3250

Treatment ... Read more >

Single dose rATG for rejection

Status: Enrolling

Investigator: Ahmed Gaber

Study Coordinator: Darrel Cleere

Phone: 713.441.6232

Rabbit antithymocyte globulin (rATG) is approved for the treatment of acute rejection following kidney transplantation and is routinely administered as a series of 5-7 consecutive daily doses via central intravenous catheter. This prolonged cour ... Read more >

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Michelle Guthrie

Phone: 713.441.6564

RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and ... Read more >

Live Chat Available